Literature DB >> 22030119

Meta-analysis of clear cell renal cell carcinoma gene expression defines a variant subgroup and identifies gender influences on tumor biology.

A Rose Brannon1, Scott M Haake, Kathryn E Hacker, Raj S Pruthi, Eric M Wallen, Matthew E Nielsen, W Kimryn Rathmell.   

Abstract

BACKGROUND: Clear cell renal cell carcinoma (ccRCC) displays molecular and histologic heterogeneity. Previously described subsets of this disease, ccA and ccB, were defined based on multigene expression profiles, but it is unclear whether these subgroupings reflect the full spectrum of disease or how these molecular subtypes relate to histologic descriptions or gender.
OBJECTIVE: Determine whether additional subtypes of ccRCC exist and whether these subtypes are related to von Hippel-Lindau (VHL) inactivation, hypoxia-inducible factor (HIF) 1 and 2 expression, tumor histology, or gender. DESIGN, SETTING, AND PARTICIPANTS: Six large, publicly available ccRCC gene expression databases were identified that cumulatively provided data for 480 tumors for meta-analysis via meta-array compilation. MEASUREMENTS: Unsupervised consensus clustering was performed on the meta-arrays. Tumors were examined for the relationship of multigene-defined consensus subtypes and expression signatures of VHL mutation and HIF status, tumor histology, and gender. RESULTS AND LIMITATIONS: Two dominant subsets of ccRCC were observed. However, a minor third cluster was revealed that correlated strongly with a wild type (WT) VHL expression profile and indications of variant histologies. When variant histologies were removed, ccA tumors naturally divided by gender. This technique is limited by the potential for persistent batch effect, tumor sampling bias, and restrictions of annotated information.
CONCLUSIONS: The ccA and ccB subsets of ccRCC are robust in meta-analysis among histologically conventional ccRCC tumors. A third group of tumors was identified that may represent a new variant of ccRCC. Within definitively clear cell tumors, gender may delineate tumors in such a way that it could have implications regarding current treatments and future drug development.
Copyright © 2011 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22030119      PMCID: PMC3244546          DOI: 10.1016/j.eururo.2011.10.007

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  24 in total

Review 1.  Transcriptional paradigms in mammalian mitochondrial biogenesis and function.

Authors:  Richard C Scarpulla
Journal:  Physiol Rev       Date:  2008-04       Impact factor: 37.312

Review 2.  Basic research in kidney cancer.

Authors:  Egbert Oosterwijk; W Kimryn Rathmell; Kerstin Junker; A Rose Brannon; Frédéric Pouliot; David S Finley; Peter F A Mulders; Ziya Kirkali; Hirotsugo Uemura; Arie Belldegrun
Journal:  Eur Urol       Date:  2011-07-05       Impact factor: 20.096

Review 3.  Renal cell carcinoma: where will the state-of-the-art lead us?

Authors:  A Rose Brannon; W Kimryn Rathmell
Journal:  Curr Oncol Rep       Date:  2010-05       Impact factor: 5.075

4.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

5.  Collecting system invasion in renal cell carcinoma: impact on prognosis and future staging strategies.

Authors:  Ganesh S Palapattu; Allan J Pantuck; Fred Dorey; Jonathon W Said; Robert A Figlin; Arie S Belldegrun
Journal:  J Urol       Date:  2003-09       Impact factor: 7.450

6.  Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney.

Authors:  Rameen Beroukhim; Jean-Philippe Brunet; Arianna Di Napoli; Kirsten D Mertz; Apryle Seeley; Maira M Pires; David Linhart; Robert A Worrell; Holger Moch; Mark A Rubin; William R Sellers; Matthew Meyerson; W Marston Linehan; William G Kaelin; Sabina Signoretti
Journal:  Cancer Res       Date:  2009-06-01       Impact factor: 12.701

7.  HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma.

Authors:  John D Gordan; Priti Lal; Vijay R Dondeti; Richard Letrero; Krishna N Parekh; C Elisa Oquendo; Roger A Greenberg; Keith T Flaherty; W Kimryn Rathmell; Brian Keith; M Celeste Simon; Katherine L Nathanson
Journal:  Cancer Cell       Date:  2008-12-09       Impact factor: 31.743

8.  Gene expression profiling predicts survival in conventional renal cell carcinoma.

Authors:  Hongjuan Zhao; Börje Ljungberg; Kjell Grankvist; Torgny Rasmuson; Robert Tibshirani; James D Brooks
Journal:  PLoS Med       Date:  2005-12-06       Impact factor: 11.069

9.  Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1.

Authors:  David A Barbie; Pablo Tamayo; Jesse S Boehm; So Young Kim; Susan E Moody; Ian F Dunn; Anna C Schinzel; Peter Sandy; Etienne Meylan; Claudia Scholl; Stefan Fröhling; Edmond M Chan; Martin L Sos; Kathrin Michel; Craig Mermel; Serena J Silver; Barbara A Weir; Jan H Reiling; Qing Sheng; Piyush B Gupta; Raymond C Wadlow; Hanh Le; Sebastian Hoersch; Ben S Wittner; Sridhar Ramaswamy; David M Livingston; David M Sabatini; Matthew Meyerson; Roman K Thomas; Eric S Lander; Jill P Mesirov; David E Root; D Gary Gilliland; Tyler Jacks; William C Hahn
Journal:  Nature       Date:  2009-10-21       Impact factor: 49.962

10.  Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes.

Authors:  Gillian L Dalgliesh; Kyle Furge; Chris Greenman; Lina Chen; Graham Bignell; Adam Butler; Helen Davies; Sarah Edkins; Claire Hardy; Calli Latimer; Jon Teague; Jenny Andrews; Syd Barthorpe; Dave Beare; Gemma Buck; Peter J Campbell; Simon Forbes; Mingming Jia; David Jones; Henry Knott; Chai Yin Kok; King Wai Lau; Catherine Leroy; Meng-Lay Lin; David J McBride; Mark Maddison; Simon Maguire; Kirsten McLay; Andrew Menzies; Tatiana Mironenko; Lee Mulderrig; Laura Mudie; Sarah O'Meara; Erin Pleasance; Arjunan Rajasingham; Rebecca Shepherd; Raffaella Smith; Lucy Stebbings; Philip Stephens; Gurpreet Tang; Patrick S Tarpey; Kelly Turrell; Karl J Dykema; Sok Kean Khoo; David Petillo; Bill Wondergem; John Anema; Richard J Kahnoski; Bin Tean Teh; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2010-01-06       Impact factor: 49.962

View more
  37 in total

1.  Alternate Metabolic Programs Define Regional Variation of Relevant Biological Features in Renal Cell Carcinoma Progression.

Authors:  Samira A Brooks; Amir H Khandani; Julia R Fielding; Weili Lin; Tiffany Sills; Yueh Lee; Alexandra Arreola; Mathew I Milowsky; Eric M Wallen; Michael E Woods; Angie B Smith; Mathew E Nielsen; Joel S Parker; David S Lalush; W Kimryn Rathmell
Journal:  Clin Cancer Res       Date:  2016-01-19       Impact factor: 12.531

Review 2.  Personalized Management of Advanced Kidney Cancer.

Authors:  Jeffrey Graham; Daniel Y C Heng; James Brugarolas; Ulka Vaishampayan
Journal:  Am Soc Clin Oncol Educ Book       Date:  2018-05-23

Review 3.  Gender differences in incidence and outcomes of urothelial and kidney cancer.

Authors:  Ilaria Lucca; Tobias Klatte; Harun Fajkovic; Michela de Martino; Shahrokh F Shariat
Journal:  Nat Rev Urol       Date:  2015-10       Impact factor: 14.432

4.  ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma.

Authors:  Samira A Brooks; A Rose Brannon; Joel S Parker; Jennifer C Fisher; Oishee Sen; Michael W Kattan; A Ari Hakimi; James J Hsieh; Toni K Choueiri; Pheroze Tamboli; Jodi K Maranchie; Peter Hinds; C Ryan Miller; Matthew E Nielsen; W Kimryn Rathmell
Journal:  Eur Urol       Date:  2014-02-25       Impact factor: 20.096

5.  FUT11 as a potential biomarker of clear cell renal cell carcinoma progression based on meta-analysis of gene expression data.

Authors:  Elżbieta Zodro; Marcin Jaroszewski; Agnieszka Ida; Tomasz Wrzesiński; Zbigniew Kwias; Hans Bluyssen; Joanna Wesoly
Journal:  Tumour Biol       Date:  2013-12-08

Review 6.  Tumour and patient factors in renal cell carcinoma-towards personalized therapy.

Authors:  Ahmed Q Haddad; Vitaly Margulis
Journal:  Nat Rev Urol       Date:  2015-04-14       Impact factor: 14.432

Review 7.  State of the science: an update on renal cell carcinoma.

Authors:  Eric Jonasch; P Andrew Futreal; Ian J Davis; Sean T Bailey; William Y Kim; James Brugarolas; Amato J Giaccia; Ghada Kurban; Armin Pause; Judith Frydman; Amado J Zurita; Brian I Rini; Pam Sharma; Michael B Atkins; Cheryl L Walker; W Kimryn Rathmell
Journal:  Mol Cancer Res       Date:  2012-05-25       Impact factor: 5.852

Review 8.  Renal cell carcinoma: Evolving and emerging subtypes.

Authors:  Suzanne M Crumley; Mukul Divatia; Luan Truong; Steven Shen; Alberto G Ayala; Jae Y Ro
Journal:  World J Clin Cases       Date:  2013-12-16       Impact factor: 1.337

Review 9.  Insights into the Genetic Basis of the Renal Cell Carcinomas from The Cancer Genome Atlas.

Authors:  Scott M Haake; Jamie D Weyandt; W Kimryn Rathmell
Journal:  Mol Cancer Res       Date:  2016-06-21       Impact factor: 5.852

10.  Next-generation sequencing of translocation renal cell carcinoma reveals novel RNA splicing partners and frequent mutations of chromatin-remodeling genes.

Authors:  Gabriel G Malouf; Xiaoping Su; Hui Yao; Jianjun Gao; Liangwen Xiong; Qiuming He; Eva Compérat; Jérôme Couturier; Vincent Molinié; Bernard Escudier; Philippe Camparo; Denaha J Doss; Erika J Thompson; David Khayat; Christopher G Wood; Willie Yu; Bin T Teh; John Weinstein; Nizar M Tannir
Journal:  Clin Cancer Res       Date:  2014-06-04       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.